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Abstract
Background: Along with obesity, physical inactivity, and family history of metabolic disorders, African American
ethnicity is a risk factor for type 2 diabetes (T2D) in the United States. However, little is known about the
differences in gene expression and transcriptomic profiles of blood in T2D between African Americans (AA) and
Caucasians (CAU), and microarray analysis of peripheral white blood cells (WBCs) from these two ethnic groups will
facilitate our understanding of the underlying molecular mechanism in T2D and identify genetic biomarkers
responsible for the disparities.
Results: A whole human genome oligomicroarray of peripheral WBCs was performed on 144 samples obtained
from 84 patients with T2D (44 AA and 40 CAU) and 60 healthy controls (28 AA and 32 CAU). The results showed
that 30 genes had significant difference in expression between patients and controls (a fold change of <-1.4 or
>1.4 with a P value <0.05). These known genes were mainly clustered in three functional categories: immune
responses, lipid metabolism, and organismal injury/abnormaly. Transcriptomic analysis also showed that 574 genes
were differentially expressed in AA diseased versus AA control, compared to 200 genes in CAU subjects. Pathway
study revealed that “Communication between innate and adaptive immune cells"/"Primary immunodeficiency
signaling” are significantly down-regulated in AA patients and “Interferon signaling"/"Complement System” are
significantly down-regulated in CAU patients.
Conclusions: These newly identified genetic markers in WBCs provide valuable information about the
pathophysiology of T2D and can be used for diagnosis and pharmaceutical drug design. Our results also found
that AA and CAU patients with T2D express genes and pathways differently.
Background
Type 2 diabetes (T2D) is the most common form dia-
betes, and it accounts for more than 90% of all diag-
nosed diabetic cases [1]. It is a heterogeneous and
multi-factorial disease. Although the exact pathogenesis
has not been fully understood, older age, family history,
physical inactivity and race/ethnicity are important risk
factors[1,2]. African American (AA) is the ethnicity with
the highest incidence and mortality rate of T2D.
According to 2010 statistics of adults aged 20 years or
older, 15.7 million non-Hispanic whites have diabetes
(10.2% of the ethnic group), compared to 4.9 million
non-Hispanic blacks (18.7%). After adjusting for popula-
tion age differences, AAs are 1.8 times as likely to have
diabetes as CAUs at similar ages [3-5]. In addition, obe-
sity and immune/inflammatory processes contribute to
the onset of T2D [6-9]. For example, elevated levels of
circulating IL-1b, IL-6, TNFa, and acute phase proteins
in T2D have been extensively described in several
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studies. That may reflect the activation of innate
immune cells by excessive levels of nutrient concentra-
tion, including glucose and free fatty acids. In turn, both
IL-6 and IL-1b act on the liver to produce a characteris-
tic dyslipidemia in metabolic syndrome, one which man-
ifests as increased very low density lipoprotein (VLDL)
and decreased high density lipoprotein (HDL) [10,11].
IL-6 and tumor necrosis factor TNFa also participate in
the impairment of insulin signaling in adipocytes [12].
Many clinical and epidemiological studies have been
done to elucidate environmental contribution to T2D
[13-15]. Microarray analysis will allow us to study
genetic contribution and patterns of altered gene expres-
sion related to T2D. Thus far, human skeletal muscles,
liver, adipose tissues, and pancreatic b-cells [16-22] have
been chosen for gene expression assay in T2D. These
studies have yielded important insights into the patho-
genesis of T2D and its relationship to obesity. For exam-
ple, adipose tissue gene expression has been found to
show more differences between T2D and healthy control
than muscle tissue gene expression. Many genes are
inflammatory and metabolically important [23]. Because
it is difficult to obtain permission from a clinic to use
tissue samples such as liver, adipose, and muscle for
genetic studies, the peripheral blood could be a conveni-
ent source of cells for this study. To date, only one
microarray study of human peripheral blood has been
reported by Grayson et al [24]. Their finding indicated
that genes differentially expressed in T2D have key roles
in T-cell activation and signaling, but this study used a
limited sample size (n = 6) and lacked ethnicity infor-
mation. In this study, we measured the up/down regula-
tion of some T2D-related genes using white blood cells
from T2D patients, and we compared the gene expres-
sion profiles between two ethnic groups. The informa-
tion obtained from our study would provide further
understanding of the pathogenesis of T2D and the dis-
parities in expression profiles between AA and CAU.
Results
Characteristics of studied subjects
This study comprised a balanced distribution of the stu-
died subjects in gender and ethnicity: among 60 con-
trols, 28 were AA including 14 females and 14 males,
and 32 were CAU including 14 females and 20 males.
Among 84 patients with T2D, 44 were AA including 22
females and 22 males, and 40 were CAU including 23
females and 17 males. As compared to AA, CAU had a
significantly higher level of blood triglycerides (TG) in
both the controls (106 ± 54.3 mg/dl in AA vs. 153 ±
77.8 mg/dl in CAU, p = 0.0009), and the patients (157 ±
128 mg/dl in AA vs. 207 ± 98.3 mg/dl in CAU, p =
0.037). There were no significant differences in other
studied clinical parameters between two races (data for
ethnicity differences were not shown). As compared to
all controls (mixed), the patients group was 4.5 years
older, had significantly higher body mass index (BMI),
blood TG, and fasting glucose, and had lower high den-
sity apolipoprotein (HDL). There were no differences in
low density apolipoproteins (LDL) and total cholesterols
(Table 1) between controls and T2D patients.
Identification of differentially expressed genes between
all T2D patients and healthy controls
Whole human genome (4 × 44K) oligo-microarrays of
peripheral WBCs from 60 healthy subjects and 84 T2D
subjects were performed. Of 41,000 probes available on
the Agilent arrays, we identified 30 genes that were dif-
ferentially expressed (a fold change of <-1.4 or >1.4 with
a P value <0.05). Six known genes were up-regulated,
including erythroid associated factor (ERAF), delta-ami-
nolevulinate synthase 2 (ALAS2), oxysterol binding pro-
tein 2 (OSBP2), carbonic anhydrase I (CA1), serine/
threonine/tyrosine kinase 1 (STYK1), and Zinc finger
protein 2 (ZIC2). Sixteen known genes were down-regu-
lated, including G0/G1 switch 2 (GOS2); telomerase-
associated protein 1 (TEP1); prostaglandin-endoperoxide
synthase 2 (PTGS2); interleukin 4 (IL4); interleukin 8
(IL8); interferon alpha-inducible protein 27 (IFI27);
interferon-induced protein with tetratricopeptide repeats
3 (IFIT3); interferon-induced protein with tetratricopep-
tide repeats 2 (IFIT2); tumor necrosis factor alpha-
induced protein 6T (NFAIP6); radical S-adenosyl
methionine domain containing 2 (RSAD2); apolipopro-
tein B mRNA editing enzyme, catalytic polypeptide-like
3A (APOBEC3A); ATP/GTP binding protein-like 4
(ABGL4); ATP-binding cassette sub-family A transporter
(ABCA1); epithelial stromal interaction 1 isoform 2
(EPSTI1); Ephrin type-A receptor 6 (EPHA6); and leu-
cine rich repeat neuronal protein 3 (LRRN3). Most of
these genes belonged to three functional categories:
Table 1 The clinical characteristics of the study subjects
Normal controls Diabetic
(n = 60) (n = 84)
Age, yr (mean ± SD) 58.5 ± 16.1 63 ± 13
Sex (female/male) 28/32 45/39
Race 32 Caucasian 40 Caucasian
28 African American 44 African American
Body mass index (kg/m2) 30.1 ± 7.3 34.2 ± 8.4**
Triacylglycerol (mg/dL) 134 ± 76.9 186 ± 113.8**
HDL cholesterol (mg/dL) 56.6 ± 17.5 49.1 ± 15.4**
LDL cholesterol (mg/dL) 112 ± 44.8 109.8 ± 36.5
Total cholesterol (mg/dL) 197 ± 44.8 195 ± 46.8
Glucose (mg/dL) 88.8 ± 10.8 142.7 ± 56.8***
Data are mean ± SD. Statistical analyses were performed using the Student’s
t-Test. **p < 0.05 ***p < 0.001, values are based on differences from controls.
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immune and inflammatory responses, such as IL-4, IL-8,
TNFAIP6, and PTGS2; lipid and glucose metabolism,
such as ABCA1, OSBP2, and GOS2; and organismal
injury and abnormalities, such as APOBEC3A. Thus,
these genes might be the genetic signatures for T2D.
Ethnic differences in gene expression profiles
In order to study ethnic disparities, gene expression
profiles between AA and CAU participants were ana-
lyzed and compared. Based on the same criteria
described before, many more genes were found to be
differentially expressed. 574 genes were differentially
expressed in AA (28 healthy controls and 44 T2D
patients) compared to 200 genes in CAU (32 healthy
controls and 40 T2D patients). In the AA group, there
were 294 down-regulated and 269 up-regulated genes
in T2D patients; however, we only saw 134 down-regu-
lated and 47 up-regulated genes in CAU T2D patients
(Figure 1a and 1b). It was obvious that AA T2D
patients had 2-6 times more altered genes than CAU
T2D patents. Table 2 summarizes the top 10 up-regu-
lated and down-regulated genes in different ethnic
groups (a fold change of <-1.4 or >1.4 with a P value
<0.05). Overlap analysis showed that AA had an
entirely different spectrum of genetic signatures for
T2D, because only one down-regulated gene and one
up-regulated gene were common between the two eth-
nicities (Figure 1a and 1b).
Ethnic differences in pathway enrichment analysis
Gene expression profiling study showed ethnic dispari-
ties in this study cohort as described above. Because
one pathway usually involves many different genes, it
is not clear whether the differentially expressed genes
in the two ethnic groups involved the same pathways.
Using the tool of Ingenuity Canonical Pathways Analy-
sis, the differentially expressed genes in two ethnic
groups were clustered into various pathways. The top
10 down-regulated and up-regulated pathways were
identified for T2D patients in AA and in CAU as
shown in Figure 2. Similar to the results of differen-
tially expressed single genes, the two T2D patient
groups had different spectra of down- and up-regu-
lated pathways. For example, significant enrichments
of down-regulated pathways in AA patients were
“communication between innate and adaptive immune
cells” and “primary immunodeficiency signaling”,
whereas those in CAU patients were “interferon signal-
ing” and “complement system” pathways. The main
up-regulated pathways in AA included “inositol meta-
bolism”, “Wnt/b-catenin signaling”, and “LXR/RXR
activation”, but for CAU they were “tight junction sig-
naling”, “cleavage and polyadenyation of pre-mRNA”,
and “methane metabolism”.
Microarray validation by real-time PCR
To confirm the accuracy of the results in microarray
study, real-time PCR were performed on 5 randomly
selected genes (ABCA1, IL-4, IL-8 and PTGS2 except
ALAS2) that were found to be differentially expressed in
microarray analysis. All of these genes have a known
function in glucose and lipid metabolism and in
immune responses. The fold changes for the transcripts
of these genes were normalized to the transcripts of gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH);
information of primers for the 5 selected genes and
GAPDH was shown in table 3. The fold changes of
those five gene expressions, as determined by microarray
and real-time PCR, are shown in Figure 3. The results
validated our microarray data.
Figure 1 Venn diagrams for down-regulated and up-regulated genes in all mixed, AA and CAU T2D patients. a) Significantly down-
regulated genes in mixed T2D patients are represented in red, AA in blue, and CAU in green. (b) Significantly up-regulated genes in mixed T2D
patients are represented in red, AA in blue, and CAU in green.
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Discussion
Previous studies of gene expression in T2D have been
restricted to adipose tissue and muscle or to animal mod-
els with limited sample size [16-22]. Before our study, the
comparison of blood gene expression in AA and CAU
with T2D patients was lacking. Our analysis of gene
profiling in peripheral WBCs from a larger number of
sample and ethnic groups begins to fill the gaps. We
showed that 30 genes are differentially expressed in T2D
patients when compared with healthy controls. Further-
more, we demonstrated that different gene expression
signatures are present in AA and CAU patients.
Table 2 Differentially expressed top 10 genes in two ethnic groups
African American Caucasian
Up-regulated Down-regulated Up-regulated Up-regulated
Gene name Fold* Gene name Fold* Gene name Fold* Gene name Fold*
IRX5 1.9 HLA-DQA1 -2.4 OLFM4 1.9 DDX3Y -3.1
THC2540257 1.8 MED18 -2.3 ENST00000382691 1.8 IFI27 -2.5
THC2521898 1.8 THC2667190 -1.8 CEACAM8 1.6 DB160230 -2.4
WDR49 1.8 GNL3L -1.8 WIF1 1.6 CYorf15B -2.4
RNF150 1.8 CENPI -1.8 AI796347 1.6 BTNL8 -2.3
AK095945 1.8 RNF125 -1.7 HLA-DQA2 1.6 EGR1 -2.3
AA579646 1.8 BU627449 -1.7 W60781 1.5 BQ213856 -2.1
THC2576067 1.7 ITIH5 -1.7 OR51B2 1.5 EGR2 -2.0
BQ934520 1.7 AK097130 -1.7 A_32_P58705 1.5 SIGLEC1 -1.9
A_24_P533990 1.7 ATM -1.7 CPSF2 1.5 IFIT1 -1.8
* Fold was the ratio of T2D patient to control in each group. The differences in all listed genes.
between T2D patients and controls were <0.05.
Figure 2 Pathway analyses using specifically regulated genes in AA and CAU. The top ten pathways were selected to present for
specifically up- or down-regulated genes in AA and CAU patients. The significantly different genes were chosen to run the Ingenuity pathway
tool. The bigger the -log(p-value) of a pathway is, the more significantly the pathway is regulated. The threshold lines represent a p value with
0.05.
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In T2D, we see increased expression of six genes in
which five of those have not been previously reported in
gene expression studies. ERAF is associated with haemo-
globin stabilization [25], ALAS2 is involved in immune
responses [26], OSBP2 in lipid metabolism [27], STYK1
in signal transduction [28], and ZIC2 in transcriptional
regulation [29]. Carbonic anhydrase I, encoded by CA1,
has been reported to be progressively increased in the
urine of T2D patients [30]. Interestingly, in our study,
we found no evidence for up-regulation of classical
inflammatory markers including the interleukin family,
the TNF family, or interferon family which have been
shown in the literature [5-9]; however, a panel of genes
belonging to those families is down-regulated in our
study cohort, including PTGS2, IL4, IL8, IFI27, IFIT3,
IFIT2, TNFAIP6, RSAD2, and AGBL4. All of those are
associated with the interferon signaling pathway,
immune signaling pathways involved in inflammatory
processes [31]. Our results suggested that the innate
immunity was actually compromised, and significantly
lower inflammation was observed in T2D patients.
These novel findings are inconsistent with the results
from other studies, which may indicate an important
difference in the pathophysiology of T2D between the
tissues. A recent study [32] also showed that elevated
levels of circulating inflammatory markers in T2D may
not necessarily reflect the degree of inflammation in
individual tissues because of the mass difference. In
summary, peripheral WBC gene expression profiling
may not mirror the changes of gene expression within a
specific tissue such as adipose or muscle.
In addition to inflammatory markers, we found down-
regulation of several genes (for example ABCA1 and
GOS2) which are reported to be associated with lipid
metabolism and T2D in gene knockout cell lines and/or
animal models [33-35]. For example, recent studies have
shown that ATP-binding cassette transporters ABCA1
and ABCG1 play important roles in macrophage choles-
terol efflux to serum or HDL in macrophage foam cells
[33]. Mice lacking ABCA1 and ABCG1 accumulate
Table 3 Primers for quantitative real time PCR experiments
Gene Forward primer Reverse primer
ABCA1 5’-TGTCCAGTCCAGTAATGGTTCTGT-3’ 5’-CGAGATATGGTCCGGATTGC-3’
ALAS2 5’-GCCGCCGAATTCAAACTTGAATTTTCAT-3’ 5’GCCGCCGAATTCGCCCTTCTGTACTGTTT-3’
IL4 5’-CCGTAACAGACATCTTTGCTGCC-3’ 5’-GAGTGTCCTTCTCATGGTGGCT-3’
IL8 5’-GAGAGTGATTGAGAGTGGACCAC-3’ 5’-CACAACCCTCTGCACCCAGTTT-3’
PTGS2 5’-TATGTTCTCCTGCCTACTGGAA-3’ 5’-GCCCTTCACGTTATTGCAGATG-3’
Figure 3 Expression concordance between microarray and quantitative real-time PCR assays. The y-axis represents the ratio of expression
values between the T2D and control groups.
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inflammatory macrophage foam cells in various tissues
such as lung, liver, spleen, or myocardium [34]. There-
fore, ABCA1 may have a unique role in dampening
inflammation. Consistent with their finding, our data
showed that ABCA1 gene was down-regulated in T2D
patients. In addition, we also see that patients had sig-
nificant lower HDL when compared with control sub-
jects (Table 1). To our knowledge, this is the first
evidence that lower expression of ABCA1 decreases the
cholesterol efflux from macrophage, resulting in less
HDL formation in T2D patients. In turn, the anti-
inflammatory and immunosuppressive functions of
ABCA1 are diminished.
Yang et al., [35] recently reported that G0S2 expres-
sion was significantly reduced in white adipose tissues
(WAT) of db/db mice and high-fat-fed wild-type mice.
They speculated that decreased insulin sensitivity of adi-
pocytes may lead to the down-regulation of G0S2, but
they are not sure whether expression of G0S2 is also
decreased in obese humans. Our gene expression profil-
ing provided strong evidence that GOS2 was down-
regulated in T2D patients, who also had significant
higher BMI compared tohealthy controls.
Type 2 diabetes (T2D) is a complex disease. Although
the exact pathogenesis has not been fully understood,
family history, physical inactivity, socioeconomic condi-
tion, and race/ethnicity contribute to the onset of T2D
[13-15]. AAs have the highest incidence and mortality
rate of T2D [5]. To better understand the health dispar-
ity, we compared the clinical parameters and expression
profiles of peripheral WBCs from AA and CAU. As
described previously, CAU had a significantly higher
level of blood triglycerides (TG) in both the controls
and the patients. There was no significant difference in
other clinical parameters between two races. However,
as shown in Figure 1, AA T2D patients had 2-6 times
more altered genes than CAU T2D patients. In AAs,
there were 294 down-regulated and 269 up-regulated
genes in T2D patients; however, we only saw 134 down-
regulated and 47 up-regulated genes in CAUs. The dif-
ferences were also observed in the top 10 up-regulated
and down-regulated genes from the two ethnic groups
shown in table 3. None of the up- or down-regulated
genes overlapped between AAs and CAUs. In agreement
with gene expression differences, pathway enrichment
study further suggested that AAs have different patho-
physiological mechanisms of T2D from CAU. For exam-
ple, significant enrichments of top 10 down-regulated
pathways in AA patients included “communication
between innate and adaptive immune cells” and “pri-
mary immunodeficiency signaling”, whereas that in CAU
patients were “interferon signaling” and “complement
system” pathways. The main up-regulated pathways in
AA were “inositol metabolism”, “Wnt/b-catenin
signaling” and “LXR/RXR activation”, but these path-
ways were not significantly altered in CAU. Taken
together, differences between AA and CAU participants
in expression profiles parallel differences between these
groups in pathway enrichment data. Ethnic differences
in TG cannot explain ethnic disparities. The possibility
that CAU persons have systematically higher levels of
TG warrants further study.
Conclusions
In summary, through the analyses of clinical parameters,
expression profiles of T2D, and ethnic differences of
gene expression and pathway enrichment, we found that
the innate immunity was compromised and significantly
lower inflammation was associated with T2D. The newly
identified ABCA1 and GOS2 in human could be used as
genetic markers for diagnosis and pharmaceutical drug
design. Our results also indicated that genes and path-
ways are differentially expressed between AA and CAU
T2D patients.
Materials and methods
Subjects and clinical laboratory data
The study was approved by the Institutional Review
Board of Tougaloo College. All subjects provided writ-
ten informed consent for this study. T2D was diagnosed
based on American Diabetes Association (ADA) guide-
lines [5] and characteristic symptoms of diabetes: a
higher BMI and a fasting plasma glucose > 126 mg dl-1
or a 2 h plasma glucose during an oral glucose tolerance
test of > 200 mg dl-1. A total of 144 blood samples from
healthy controls (n = 60, 32 Caucasians and 28 African
Americans), and T2D (n = 84, 40 Caucasians and 44
African Americans) were collected. All subjects were
evaluated by age, sex, ethnicity, body mass index (BMI),
triacylglycerol (TG), high-density lipoprotein (HDL),
low-density lipoprotein (LDL), total cholesterol (TC),
and glucose levels.
RNA isolation
Total RNA from 8-10 mLs peripheral blood WBCs was
obtained using LeukoLock™ Total RNA system
(Ambion Inc, Austin, TX) according to the manufac-
turer’s instructions. The quantity and quality of the iso-
lated RNA were determined by Nanodrop
spectrophotometry and Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA).
Microarray experiments
Gene expression profiling was conducted using Agilent
Whole Human Genome1 (4 × 44K) Oligo arrays with
~20,000 genes represented (Agilent Technologies, Palo
Alto, CA). Each sample was hybridized against a human
universal RNA control (Stratagene, La Jolla, CA). 500 ng
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of total RNA was amplified and labeled using the Agi-
lent Low RNA Input Fluorescent Linear Amplification
Kit, according to manufacturer’s protocol. For each two
color array, 850 ng of each Cy5- (universal control) and
Cy3-labeled (sample) cRNA were mixed and fragmented
using the Agilent In Situ Hybridization Kit protocol.
Hybridizations were performed for 17 hours in a rotat-
ing hybridization oven according to the Agilent 60-mer
oligo microarray processing protocol prior to washing
and scanning with an Agilent Scanner (G2565AA, Agi-
lent Technologies, Wilmington, DE). Arrays were pro-
cessed and background corrected with default settings
for all parameters with the Agilent Feature Extraction
software (v.9.5.3.1).
Microarray data analysis
Microarray data analyses were processed with Gene-
Spring version 7.0 and 10.0. The sample quality control
was based on the Pearson correlation of a sample with
other samples in the whole experiment. If the average
Pearson correlation with other samples was less than
80%, the sample was excluded for further analysis. If the
scanned intensity was less than 5.0 for a probe, it was
transformed to 5. A perchip (within) array normalization
was performed using 50 percentile values of all the
probe values in the array. Per gene (between) array nor-
malization was also applied using the median value of a
gene across all samples in the experiment. Probe fea-
tures were first filtered using flags. A “present” or
“absent” flag was defined using the Agilent Feature
Extraction 9.5.1 software. Only a probe that had present
flags in at least 50% samples of all the arrays was kept
for further analysis. Data were subsequently log (base 2)
transformed for statistical analysis. To identify differen-
tiated genes between two groups (e g. normal vs. dia-
betes), an un-paired t-test with cut off p value 0.05 was
applied to compare control samples and TNT exposed
samples. In addition, 1.4 fold changes were applied to
identify more significantly regulated genes.
Gene functional analysis and pathway analysis
Significantly regulated probes were employed for one
way hierarchical clustering (only cluster genes) or two-
way hierarchical clustering (clustering both genes and
samples) using GeneSpring 7.0 and/or 10 (Agilent Tech-
nologies, Foster City, CA, USA). A Pearson correlation
with average linkage was applied for the clustering.
Gene functional categories were classified according to
Gene Ontology (GO) [36] using The Database for
Annotation, Visualization and Integrated Discovery
(DAVID) [37,38] and Gofetch [39] tools. A Gene Ontol-
ogy functional term enrichment p value less than 0.05
was considered significant. Pathway analysis was per-
formed using the Ingenuity canonical pathways analysis
tool. Similar to GO analysis, a pathway with an enrich-
ment p value less than 0.05 was considered to be a sig-
nificantly regulated pathway (Ingenuity Systems, Inc.,
Redwood City, CA). Gene networks were constructed
based on the Ingenuity knowledge base. A score was
assigned to a network according to the fit of the original
set of significant genes. This score reflects the negative
logarithm of the p value that indicates the likelihood of
the focus genes in a network being found together due
to random chance [40].
Real-time PCR
To validate the microarray data, a real-time PCR assay
was performed using Brilliant II SYBR® Green system
for five genes. Samples were selected from the original
microarray experiments for further RT-PCR testing
based on sufficient RNA remaining. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression was
used as an internal control and the relative expression
of each gene was determined by the ΔΔCt method,
comparing expression of test gene to an average
GAPDH, and then comparing the T2D group versus
healthy control group. The primers used for cDNA
amplification are shown in Table 3.
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